Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GeneDx Holdings Corp.WGS · Entity 1634 | CHIEF TRANSFORMATION OFFICER | March 16, 2024 | March 19, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GeneDx Holdings Corp.
Report date March 16, 2024 · Filed March 19, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 29,517 |
Ending reported balance
After 2024-03-18 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-03-16 · Exercise / conversion · Acquired 5,114 · Balance 31,525 F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Row 2 · 2024-03-18 · Sale · Disposed 2,008 · Balance 29,517 F2: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction. F3: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.11 to $10.6501 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 61,362 |
Reported balance
After 2024-03-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-03-16 · Exercise / conversion · Disposed 5,114 · Balance 61,362 F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F4: 6.25% vest in quarterly installments over the 4-year period commencing on March 16, 2023 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
F2: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction.
F3: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.11 to $10.6501 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: 6.25% vest in quarterly installments over the 4-year period commencing on March 16, 2023 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 10, 2023 Filed Mar 13, 2023 23:26 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 35,200 | $0.36 | $12,664.96 |
DisclosureSEC source: 0001209191-23-018275 · doc4.xml · nonDerivative · entry 2 Saad Kareem · CIK 0001873805 · Chief Transformation Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,430 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.345 to $0.3608, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| March 09, 2023 Filed Mar 13, 2023 23:26 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 93,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-018275 · doc4.xml · derivative · entry 3 Saad Kareem · CIK 0001873805 · Chief Transformation Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,406,250 Underlying: Class A Common Stock · 93,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: 6.25% vest in quarterly installments over the 4-year period commencing on March 9, 2023 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. F4 · derivative.expiration_date: 6.25% vest in quarterly installments over the 4-year period commencing on March 9, 2023 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| March 09, 2023 Filed Mar 13, 2023 23:26 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionClass A Common Stock | 93,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-018275 · doc4.xml · nonDerivative · entry 1 Saad Kareem · CIK 0001873805 · Chief Transformation Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,630 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| January 20, 2023 Filed Jan 23, 2023 22:50 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 6,292 | $0.38 | $2,416.76 |
DisclosureSEC source: 0001209191-23-004477 · doc4.xml · nonDerivative · entry 2 Saad Kareem · CIK 0001873805 · Chief Transformation Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,487 F2 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction. Read SEC document |
| January 19, 2023 Filed Jan 23, 2023 22:50 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 18,014 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-004477 · doc4.xml · derivative · entry 3 Saad Kareem · CIK 0001873805 · Chief Transformation Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,116 Underlying: Class A Common Stock · 18,014 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: 3/16th of the total shares vested on October 25, 2021, 1/16th of the total shares vested on January 25, 2022, and thereafter will vest as to 1/16th of the total shares underlying the award in quarterly installments until fully vested on January 19, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date. F3 · derivative.expiration_date: 3/16th of the total shares vested on October 25, 2021, 1/16th of the total shares vested on January 25, 2022, and thereafter will vest as to 1/16th of the total shares underlying the award in quarterly installments until fully vested on January 19, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| January 19, 2023 Filed Jan 23, 2023 22:50 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionClass A Common Stock | 18,014 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-004477 · doc4.xml · nonDerivative · entry 1 Saad Kareem · CIK 0001873805 · Chief Transformation Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,779 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| January 04, 2023 Filed Jan 6, 2023 00:28 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | SaleClass A Common Stock | 3,170 | $0.26 | $832.13 |
DisclosureSEC source: 0001209191-23-002122 · doc4.xml · nonDerivative · entry 1 Saad Kareem · CIK 0001873805 · Chief Transformation Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,765 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.2593 to $0.2627, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| January 01, 2023 Filed Jan 5, 2023 00:56 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 9,005 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-001448 · doc4.xml · derivative · entry 2 Saad Kareem · CIK 0001873805 · Chief Transformation Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,076 Underlying: Class A Common Stock · 9,005 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: 6.25% vest in quarterly installments over the 4-year period on April 4, 2022 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date F2 · derivative.expiration_date: 6.25% vest in quarterly installments over the 4-year period on April 4, 2022 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date Read SEC document |
| January 01, 2023 Filed Jan 5, 2023 00:56 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | Exercise / conversionClass A Common Stock | 9,005 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-001448 · doc4.xml · nonDerivative · entry 1 Saad Kareem · CIK 0001873805 · Chief Transformation Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,935 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| December 09, 2022 Filed Dec 14, 2022 21:13 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | GrantRestricted Stock Unit · Derivative | 1,500,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-061184 · doc4.xml · derivative · entry 1 Saad Kareem · CIK 0001873805 · Chief Transformation Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500,000 Underlying: Class A Common Stock · 1,500,000 shares Expires 2026-12-09 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: 6.25% vest in quarterly installments over the 4-year period commencing on December 9, 2022 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| October 20, 2022 Filed Oct 21, 2022 20:07 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | SaleClass A Common Stock | 5,412 | $0.89 | $4,818.30 |
DisclosureSEC source: 0001209191-22-054258 · doc4.xml · nonDerivative · entry 2 Saad Kareem · CIK 0001873805 · Chief Transformation Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,930 F2 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs"). The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction. F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.89 to $0.91, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. Read SEC document |
| October 19, 2022 Filed Oct 21, 2022 20:07 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 18,014 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-054258 · doc4.xml · derivative · entry 3 Saad Kareem · CIK 0001873805 · Chief Transformation Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,130 Underlying: Class A Common Stock · 18,014 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: 3/16th of the total shares vested on October 25, 2021, 1/16th of the total shares vested on January 25, 2022, and thereafter will vest as to 1/16th of the total shares underlying the award in quarterly installments until fully vested on January 19, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date. F4 · derivative.expiration_date: 3/16th of the total shares vested on October 25, 2021, 1/16th of the total shares vested on January 25, 2022, and thereafter will vest as to 1/16th of the total shares underlying the award in quarterly installments until fully vested on January 19, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| October 19, 2022 Filed Oct 21, 2022 20:07 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | Exercise / conversionClass A Common Stock | 18,014 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-054258 · doc4.xml · nonDerivative · entry 1 Saad Kareem · CIK 0001873805 · Chief Transformation Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,342 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 00:53 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | SaleClass A Common Stock | 2,669 | $0.94 | $2,515.00 |
DisclosureSEC source: 0001209191-22-052572 · doc4.xml · nonDerivative · entry 2 Saad Kareem · CIK 0001873805 · Chief Transformation Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,328 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.8605 to $1.1143, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| October 01, 2022 Filed Oct 5, 2022 00:53 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 9,005 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-052572 · doc4.xml · derivative · entry 3 Saad Kareem · CIK 0001873805 · Chief Transformation Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,081 Underlying: Class A Common Stock · 9,005 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: 6.25% vest in quarterly installments over the 4-year period commencing on April 4, 2022 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. F4 · derivative.expiration_date: 6.25% vest in quarterly installments over the 4-year period commencing on April 4, 2022 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| October 01, 2022 Filed Oct 5, 2022 00:53 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | Exercise / conversionClass A Common Stock | 9,005 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-052572 · doc4.xml · nonDerivative · entry 1 Saad Kareem · CIK 0001873805 · Chief Transformation Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,997 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| July 20, 2022 Filed Jul 21, 2022 20:40 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | SaleClass A Common Stock | 5,311 | $1.60 | $8,497.60 |
DisclosureSEC source: 0001209191-22-042863 · doc4.xml · nonDerivative · entry 2 Saad Kareem · CIK 0001873805 · Chief Transformation Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,992 F2 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs"). The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction. Read SEC document |
| July 19, 2022 Filed Jul 21, 2022 20:40 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 18,014 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-042863 · doc4.xml · derivative · entry 3 Saad Kareem · CIK 0001873805 · Chief Transformation Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,144 Underlying: Class A Common Stock · 18,014 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: 3/16th of the total shares vested on October 25, 2021, 1/16th of the total shares vested on January 25, 2022, and thereafter will vest as to 1/16th of the total shares underlying the award in quarterly installments until fully vested on January 19, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date. F3 · derivative.expiration_date: 3/16th of the total shares vested on October 25, 2021, 1/16th of the total shares vested on January 25, 2022, and thereafter will vest as to 1/16th of the total shares underlying the award in quarterly installments until fully vested on January 19, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| July 19, 2022 Filed Jul 21, 2022 20:40 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | Exercise / conversionClass A Common Stock | 18,014 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-042863 · doc4.xml · nonDerivative · entry 1 Saad Kareem · CIK 0001873805 · Chief Transformation Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,303 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| July 05, 2022 Filed Apr 28, 2023 21:14 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 2,612 | $1.32 | $3,444.44 |
DisclosureSEC source: 0001209191-23-026074 · doc4.xml · nonDerivative · entry 2 Saad Kareem · CIK 0001873805 · Chief Transformation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,682 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.215 to $1.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 01, 2022 Filed Apr 28, 2023 21:14 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 9,005 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-026074 · doc4.xml · derivative · entry 3 Saad Kareem · CIK 0001873805 · Chief Transformation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,081 Underlying: Class A Common Stock · 9,005 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: 6.25% of the total shares underlying the restricted stock units vest in quarterly installments beginning on July 1, 2022 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. F4 · derivative.expiration_date: 6.25% of the total shares underlying the restricted stock units vest in quarterly installments beginning on July 1, 2022 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| July 01, 2022 Filed Apr 28, 2023 21:14 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionClass A Common Stock | 9,005 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-026074 · doc4.xml · nonDerivative · entry 1 Saad Kareem · CIK 0001873805 · Chief Transformation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,294 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| April 20, 2022 Filed Apr 21, 2022 20:21 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | SaleClass A Common Stock | 6,269 | $2.49 | $15,609.81 |
DisclosureSEC source: 0001209191-22-025168 · doc4.xml · nonDerivative · entry 2 Saad Kareem · CIK 0001873805 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,289 F2 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs"). The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction. Read SEC document |
| April 19, 2022 Filed Apr 21, 2022 20:21 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 18,014 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-025168 · doc4.xml · derivative · entry 3 Saad Kareem · CIK 0001873805 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,158 Underlying: Class A Common Stock · 18,014 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: 3/16th of the total shares vested on October 25, 2021, 1/16th of the total shares vested on January 25, 2022, and thereafter will vest as to 1/16th of the total shares underlying the award in quarterly installments until fully vested on January 19, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date. F3 · derivative.expiration_date: 3/16th of the total shares vested on October 25, 2021, 1/16th of the total shares vested on January 25, 2022, and thereafter will vest as to 1/16th of the total shares underlying the award in quarterly installments until fully vested on January 19, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| April 19, 2022 Filed Apr 21, 2022 20:21 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | Exercise / conversionClass A Common Stock | 18,014 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-025168 · doc4.xml · nonDerivative · entry 1 Saad Kareem · CIK 0001873805 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,558 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| April 04, 2022 Filed Apr 6, 2022 21:17 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | GrantRestricted Stock Unit · Derivative | 144,086 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-023518 · doc4.xml · derivative · entry 2 Saad Kareem · CIK 0001873805 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,086 Underlying: Class A Common Stock · 144,086 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F1 · derivative.exercise_date: 6.25% vest in quarterly installments over the four-year period commencing on April 1, 2022 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. F1 · derivative.expiration_date: 6.25% vest in quarterly installments over the four-year period commencing on April 1, 2022 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| April 04, 2022 Filed Apr 6, 2022 21:17 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | GrantEmployee Stock Option (Right to Buy) · Derivative | 250,150 | $0.00 Strike: $3.05 | $0.00 |
DisclosureSEC source: 0001209191-22-023518 · doc4.xml · derivative · entry 1 Saad Kareem · CIK 0001873805 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,150 Underlying: Class A Common Stock · 250,150 shares Expires 2032-04-03 F1 · derivative.exercise_date: 6.25% vest in quarterly installments over the four-year period commencing on April 1, 2022 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| January 28, 2022 Filed Feb 3, 2022 02:27 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | SaleClass A Common Stock | 6,697 | $2.84 | $19,026.18 |
DisclosureSEC source: 0001209191-22-006611 · doc4.xml · nonDerivative · entry 1 Saad Kareem · CIK 0001873805 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,544 F1 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs"). The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.84 to $2.88, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| January 25, 2022 Filed Jan 28, 2022 01:25 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 18,014 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-005285 · doc4.xml · derivative · entry 2 Saad Kareem · CIK 0001873805 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,172 Underlying: Class A Common Stock · 18,014 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: 3/16th of the total shares vested on October 25, 2021, 1/16th of the total shares vested on January 25, 2022, and thereafter will vest as to 1/16th of the total shares underlying the award in quarterly installments until fully vested on January 19, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date. F2 · derivative.expiration_date: 3/16th of the total shares vested on October 25, 2021, 1/16th of the total shares vested on January 25, 2022, and thereafter will vest as to 1/16th of the total shares underlying the award in quarterly installments until fully vested on January 19, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| January 25, 2022 Filed Jan 28, 2022 01:25 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | Exercise / conversionClass A Common Stock | 18,014 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-005285 · doc4.xml · nonDerivative · entry 1 Saad Kareem · CIK 0001873805 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,241 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| December 09, 2021 Filed Dec 14, 2021 00:10 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | GrantRestricted Stock Unit · Derivative | 62,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-069333 · doc4.xml · derivative · entry 1 Saad Kareem · CIK 0001873805 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,875 Underlying: Class A Common Stock · 62,875 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration, granted pursuant to the terms of that certain Agreement and Plan of Merger, dated as of February 9, 2021 (as amended, the "Merger Agreement"), by and among CM Life Sciences, Inc., S-IV Sub, Inc. and Mount Sinai Genomics, Inc. d/b/a Sema4. In addition, in the event that any similar RSUs are forfeited (for example, as a result of the recipient no longer being an employee of the Issuer), the Merger Agreement provides for the shares underlying such forfeited RSUs to become available for issuance to other RSU recipients. Therefore, each RSU also represents to right to receive additional shares of the Issuer's Class A Common Stock from this "forfeiture pool". The number of shares of the Issuer's Class A Common Stock that may be issued to the Reporting Person pursuant to the "forfeiture pool" is not determinable at this time. F2 · derivative.exercise_price: [cont'd from footnote 1] Any shares of the Issuer's Class A Common Stock ultimately issued to the Reporting Person in respect of each RSU will be reported in a subsequent filing. F3 · derivative.exercise_date: The vesting of the RSUs is conditioned on the satisfaction of both a service requirement and a market-based requirement. The service requirement is deemed satisfied as of the grant date with respect to 11,790 of the RSUs, and will be satisfied with respect to the remainder of the RSUs over 13 quarterly periods, subject to the Reporting Person's continued service to the Issuer on each service-based vesting date. F3 · derivative.expiration_date: The vesting of the RSUs is conditioned on the satisfaction of both a service requirement and a market-based requirement. The service requirement is deemed satisfied as of the grant date with respect to 11,790 of the RSUs, and will be satisfied with respect to the remainder of the RSUs over 13 quarterly periods, subject to the Reporting Person's continued service to the Issuer on each service-based vesting date. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 23:59 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | Tax withholdingClass A Common Stock | 1,799 | $5.52 | $9,930.48 |
DisclosureSEC source: 0001209191-21-067988 · doc4.xml · nonDerivative · entry 2 Saad Kareem · CIK 0001873805 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,227 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover certain tax obligation in connection with the stock bonus granted to the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.51 to $5.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 23:59 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | GrantClass A Common Stock | 5,592 | $6.05 | $33,831.60 |
DisclosureSEC source: 0001209191-21-067988 · doc4.xml · nonDerivative · entry 1 Saad Kareem · CIK 0001873805 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,026 F1 · shares: The indicated shares were issued to Reporting Person as a stock bonus in connection with the elimination of Issuer's sabbatical leave program, in which all employees of Issuer hired on or before June 30, 2021 were provided an opportunity to receive a stock bonus in lieu of their continued eligibility to take sabbatical leave. The stock bonus was fully vested as of the date of issuance. Read SEC document |
| October 25, 2021 Filed Nov 3, 2021 00:23 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 54,042 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-062552 · doc4.xml · derivative · entry 3 Saad Kareem · CIK 0001873805 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,186 Underlying: Class A Common Stock · 54,042 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: 3/16th of the total shares vested on October 25, 2021, 1/16th of the total shares vest on January 19, 2022, and thereafter vests as to 1/16th of the total shares underlying the award in quarterly installments until fully vested on January 19, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date. F3 · derivative.expiration_date: 3/16th of the total shares vested on October 25, 2021, 1/16th of the total shares vest on January 19, 2022, and thereafter vests as to 1/16th of the total shares underlying the award in quarterly installments until fully vested on January 19, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| October 25, 2021 Filed Nov 3, 2021 00:23 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | SaleClass A Common Stock | 16,608 | $7.54 | $125,224.32 |
DisclosureSEC source: 0001209191-21-062552 · doc4.xml · nonDerivative · entry 2 Saad Kareem · CIK 0001873805 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,434 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| October 25, 2021 Filed Nov 3, 2021 00:23 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | Exercise / conversionClass A Common Stock | 54,042 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-062552 · doc4.xml · nonDerivative · entry 1 Saad Kareem · CIK 0001873805 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,042 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| October 01, 2021 Filed Oct 6, 2021 01:45 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | GrantRestricted Stock Unit · Derivative | 288,228 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-059758 · doc4.xml · derivative · entry 2 Saad Kareem · CIK 0001873805 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 288,228 Underlying: Class A Common Stock · 288,228 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F1 · derivative.exercise_date: 3/16th of the total shares vest on October 25, 2021, 1/16th of the total shares vest on January 19, 2022, and thereafter vests as to 1/16th of the total shares underlying the award in quarterly installments until fully vested on January 19, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date. F1 · derivative.expiration_date: 3/16th of the total shares vest on October 25, 2021, 1/16th of the total shares vest on January 19, 2022, and thereafter vests as to 1/16th of the total shares underlying the award in quarterly installments until fully vested on January 19, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| October 01, 2021 Filed Oct 6, 2021 01:45 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | GrantEmployee Stock Option (Right to Buy) · Derivative | 192,152 | $0.00 Strike: $7.62 | $0.00 |
DisclosureSEC source: 0001209191-21-059758 · doc4.xml · derivative · entry 1 Saad Kareem · CIK 0001873805 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,152 Underlying: Class A Common Stock · 192,152 shares Expires 2031-09-30 F1 · derivative.exercise_date: 3/16th of the total shares vest on October 25, 2021, 1/16th of the total shares vest on January 19, 2022, and thereafter vests as to 1/16th of the total shares underlying the award in quarterly installments until fully vested on January 19, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.